CMS New Technology Add-On Payment Applications For FY 2024 Include Five Bispecific Antibodies Among 20 Drug Candidates; Likely Rebound After Small Class Of 2023

You must be a logged-in member of this site to view this article.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Alternatively, if your organization already has a license and you do not yet have an account, please click here to request access.